Literature DB >> 16901687

Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations.

Gabriella Ferrandina1, Francesco Legge, Vanda Salutari, Amelia Paglia, Antonia Testa, Giovanni Scambia.   

Abstract

Recurrence of disease represents a clinical challenge in ovarian cancer patients. The aim of this study was to analyse the distribution and pattern of recurrence and their association with clinical outcome in a large series of ovarian cancer patients. This study was conducted on 328 primary untreated ovarian cancer patients. For each relapse, information on date of clinical/instrumental recurrence, and pattern of disease presentation were retrieved. In stage III-IV cases (n = 270), diffuse abdominal carcinomatosis occurred in 62.1% of cases, while recurrences presented as a single lesion or multiple nodules occurred in 9.9% and 26.7% of cases, respectively. Pattern of recurrence as carcinomatosis was shown to be associated with unfavourable outcome even when stratified according to platinum free interval (PFI) duration. In multivariate analysis, pattern of recurrence and PFI duration retained an independent prognostic role for post-relapse survival. Duration of PFI and type of recurrence may independently influence post-relapse survival in ovarian cancer patients.

Entities:  

Mesh:

Year:  2006        PMID: 16901687     DOI: 10.1016/j.ejca.2006.03.025

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Ovarian cancer recurrence update.

Authors:  Stefano Cianci
Journal:  Gland Surg       Date:  2020-08

2.  βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma.

Authors:  Alexander Quaas; Amir-Hossein Rahvar; Christoph Burdelski; Christina Koop; Christian Eichelberg; Michael Rink; Roland Dahlem; Thorsten Schlomm; Maria Christina Tsourlakis; Ronald Simon; Sarah Minner; Guido Sauter; Stefan Steurer
Journal:  World J Urol       Date:  2014-12-21       Impact factor: 4.226

Review 3.  Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience.

Authors:  Federico Coccolini; Paola Fugazzola; Giulia Montori; Luca Ansaloni; Massimo Chiarugi
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 4.  Surgery vs. chemotherapy for ovarian cancer recurrence: what is the best treatment option.

Authors:  Vito Andrea Capozzi; Andrea Rosati; Luigi Carlo Turco; Giulio Sozzi; Matteo Riccò; Benito Chiofalo; Giuseppe Vizzielli
Journal:  Gland Surg       Date:  2020-08

5.  Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.

Authors:  Marco Petrillo; Massimo Zucchetti; Stefano Cianci; Lavinia Morosi; Carlo Ronsini; Andrea Colombo; Maurizio D'Incalci; Giovanni Scambia; Anna Fagotti
Journal:  J Gynecol Oncol       Date:  2019-03-01       Impact factor: 4.401

6.  Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome.

Authors:  Francesco Legge; Marco Petrillo; Vincenzo Adamo; Salvatore Pisconti; Giovanni Scambia; Gabriella Ferrandina
Journal:  BMC Cancer       Date:  2008-12-12       Impact factor: 4.430

7.  Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control.

Authors:  Marco Petrillo; Luigi Pedone Anchora; Giovanni Scambia; Anna Fagotti
Journal:  Oncologist       Date:  2016-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.